Andrew Schwendenman Net Worth

The estimated Net Worth of Andrew Schwendenman is at least $411 Tausend dollars as of 16 May 2024. Andrew Schwendenman owns over 2,298 units of Replimune Inc stock worth over $396,528 and over the last few years Andrew sold REPL stock worth over $14,868.

Andrew Schwendenman REPL stock SEC Form 4 insiders trading

Andrew has made over 1 trades of the Replimune Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Andrew sold 2,298 units of REPL stock worth $14,868 on 16 May 2024.

The largest trade Andrew's ever made was selling 2,298 units of Replimune Inc stock on 16 May 2024 worth over $14,868. On average, Andrew trades about 1,149 units every 0 days since 2024. As of 16 May 2024 Andrew still owns at least 38,238 units of Replimune Inc stock.

You can see the complete history of Andrew Schwendenman stock trades at the bottom of the page.

What's Andrew Schwendenman's mailing address?

Andrew's mailing address filed with the SEC is C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801.

Insiders trading at Replimune Inc

Over the last 6 years, insiders at Replimune Inc have traded over $72,652,546 worth of Replimune Inc stock and bought 2,360,000 units worth $33,565,200 . The most active insiders traders include Group, Llc Green Jeremy Red..., Capital Life Sciences Inves... und Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of $508,649. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth $90,989.

What does Replimune Inc do?

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.

Complete history of Andrew Schwendenman stock trades at Replimune Inc

Replimune Inc executives and stock owners

Replimune Inc executives and other stock owners filed with the SEC include:

• Pradeep Misra,
  Chairman of the Board, Managing Director
• Richa Misra,
  Whole-time Director
• Philip Astley-Sparke FSA,
  CEO & Director
• Dr. Robert Coffin Ph.D.,
  Founder, Pres, Chief R&D Officer and Director
• Philip Astley-Sparke,
  CEO & Director
• Vikas Gupta,
  Company Secretary and Compliance Officer
• Manoj Kumar,
  Chief Financial Officer
• Tanya N. Lewis M.S.,
  Chief Devel. Operations Officer
• Tarun Jain,
  Non-Executive Independent Director
• Himanshu Garg,
  Non-Executive Independent Director
• Jamal Ansari,
  Non-Executive Independent Director
• Dr. Colin A. Love Ph.D.,
  Chief Operating Officer
• Sushil Patel Ph.D.,
  Chief Commercial Officer
• Dr. Pamela Esposito Ph.D.,
  Chief Bus. Officer
• Dr. Colin A. Love,
  Chief Operating Officer
• Jean M. Franchi,
  Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer
• Robert Coffin,
  Director
• Veleka Peeples Dyer,
  Director
• Dieter Weinand,
  Director
• Howard Kaufman,
  Chief Medical Officer
• Stephen A Gorgol,
  Chief Accounting Officer
• Colin Love,
  Chief Operating Officer
• Capital Fund Iii Cooperatie...,
  10% owner
• Hugo Alexander Slootweg,
  Director
• Group, Llc Green Jeremy Red...,
  
• Kapil Dhingra,
  Director
• Venture Fund X, L.P.Atlas V...,
  
• Hyam Levitsky,
  Director
• Pamela Esposito,
  Chief Business Officer
• Jason P Rhodes,
  Director
• Joseph P Slattery,
  Director
• Capital Life Sciences Inves...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Philip Astley Sparke,
  Executive Chairman
• Paolo Pucci,
  Director
• Venture Fund X, L.P. Atlas,
  10% owner
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Jean M. Franchi,
  Chief Financial Officer
• Emily Luisa Hill,
  Chief Financial Officer
• Konstantinos Xynos,
  Chief Medical Officer
• Andrea Pirzkall,
  Chief Medical Officer
• Christy J. Oliger,
  Director
• Tanya Lewis,
  Chief Dev. Op. Officer
• Sushil Patel,
  Chief Executive Officer
• Christopher Sarchi,
  Chief Commercial Officer
• Andrew Schwendenman,
  Chief Accounting Officer